JNJ vs SNY

For growth investors, Sanofi (SNY) is the stronger pick with 5.

5% revenue growth year-over-year, versus 4. 3% for Johnson & Johnson (JNJ). Sanofi (SNY) offers the better valuation at 18. 1x trailing P/E (10. 1x forward), making it the more compelling value choice. Analysts rate Johnson & Johnson (JNJ) a "Buy" — based on 40 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Sanofi (SNY) is the cheapest at 18.

1x versus Johnson & Johnson at 39. 4x. On forward P/E, Sanofi is actually cheaper at 10. 1x.

Over the past 5 years, Johnson & Johnson (JNJ) delivered a total return of +55.

8%, compared to +0. 2% for Sanofi (SNY). Over 10 years, the gap is even starker: JNJ returned +132. 2% versus SNY's +58. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Johnson & Johnson (JNJ) is the lower-risk stock at -0.

03β versus Sanofi's 0. 43β — meaning SNY is approximately -1646% more volatile than JNJ relative to the S&P 500. On balance sheet safety, Sanofi (SNY) carries a lower debt/equity ratio of 30% versus 51% for Johnson & Johnson — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Sanofi (SNY) is pulling ahead at 5.

5% versus 4. 3% for Johnson & Johnson (JNJ). On earnings-per-share growth, the picture is similar: Sanofi grew EPS -7. 3% year-over-year, compared to -57. 8% for Johnson & Johnson. Over a 3-year CAGR, SNY leads at 4. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Sanofi (SNY) is the more profitable company, earning 16.

7% net margin versus 15. 8% for Johnson & Johnson — meaning it keeps 16. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JNJ leads at 24. 9% versus 13. 6% for SNY. At the gross margin level — before operating expenses — SNY leads at 72. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Sanofi (SNY) trades at 10.

1x forward P/E versus 19. 7x for Johnson & Johnson — 9. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SNY: 20. 3% to $51. 00.

All stocks in this comparison pay dividends.

Sanofi (SNY) offers the highest yield at 5. 1%, versus 2. 1% for Johnson & Johnson (JNJ).

For long-horizon retirement investors, Johnson & Johnson (JNJ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

03), 2. 1% yield, +132. 2% 10Y return). Both have compounded well over 10 years (JNJ: +132. 2%, SNY: +58. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: JNJ is a large-cap quality compounder stock; SNY is a mid-cap income-oriented stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.